A careful reassessment of anthracycline use in curable breast cancer
Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of...
Saved in:
Main Authors: | Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/aad7894979b94db08a790483d6338a18 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiac and skeletal muscle predictors of impaired cardiorespiratory fitness post-anthracycline chemotherapy for breast cancer
by: Amy A. Kirkham, et al.
Published: (2021) -
Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
by: Li-Yan Zhou, et al.
Published: (2015) -
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
by: Jason J Zoeller, et al.
Published: (2021) -
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
by: Craig Davison, et al.
Published: (2021) -
Genetic basis of anthracyclines cardiotoxicity: Literature review
by: M. Yu. Sinitsky, et al.
Published: (2021)